Description

Drotaverine is a benzylisoquinoline antispasmodic that works by selectively inhibiting phosphodiesterase-4 (PDE?4), thereby increasing cyclic AMP levels and promoting smooth muscle relaxation. It is widely used in research settings to study spasm relief in visceral organs, uterine tissue, and blood vessels due to its rapid onset and vasodilatory properties.

Product Specifications

Mechanism of Action

Drotaverine inhibits PDE?4, elevating intracellular cAMP, activating PKA, and leading to myosin light-chain kinase inhibition, which results in smooth muscle relaxation. It also contributes to vasodilation and blood flow enhancement.

Research Applications

• Gastrointestinal and biliary colic models

• Ureteric and urinary smooth muscle spasm studies

• Uterine relaxation and dysmenorrhea models

• Vascular smooth muscle and hemodynamic research

• Comparative studies of smooth muscle relaxants

Safety & Handling

• Dosage in animal studies: typically 40–80?mg IV or IM, once or twice daily.

• Side effects: possible headache, dizziness, nausea; rare arrhythmia or hypotension.

• Contraindications: hypersensitivity to drotaverine; caution in cardiovascular compromise.

• Handling: Use lab PPE. Avoid needle-stick or aerosol exposure.

• Storage: Keep sealed at 20–25?°C, protected from light and moisture.

Core Keywords

drotaverine injection, drotaverine hydrochloride, No?Spa analog, CAS 14009?24?6, HJ20183353, PDE?4 inhibitor injection, smooth muscle relaxant, biliary colic research, wholesale drotaverine ampoules

Research Use Disclaimer

This product is strictly for laboratory and research use. It is not approved for clinical, therapeutic, diagnostic, or veterinary use. Misuse may pose legal or health risks. Use only under approved institutional protocols.